Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 7 of 7 entries
Sorted by: Best Match Show Resources per page
Magnolol may contribute to barrier function improvement on imiquimod-induced psoriasis-like dermatitis animal model via the downregulation of interleukin-23.

Experimental and therapeutic medicine

Guo JW, Cheng YP, Liu CY, Thong HY, Lo Y, Wu CY, Jee SH.
PMID: 33747183
Exp Ther Med. 2021 May;21(5):448. doi: 10.3892/etm.2021.9876. Epub 2021 Mar 01.

Psoriasis is a chronic, recurrent, immune-mediated disease involving the skin and joints. Epidermal hyperproliferation, abnormal keratinocyte differentiation, angiogenesis with blood vessel dilatation, and excess T helper type-1 (Th-1) and Th-17 cell infiltration are the main histopathological features of psoriasis....

Cite
Guo JW, Cheng YP, Liu CY, et al. Magnolol may contribute to barrier function improvement on imiquimod-induced psoriasis-like dermatitis animal model via the downregulation of interleukin-23. Exp Ther Med. 2021;21(5):448doi: 10.3892/etm.2021.9876.
Guo, J. W., Cheng, Y. P., Liu, C. Y., Thong, H. Y., Lo, Y., Wu, C. Y., & Jee, S. H. (2021). Magnolol may contribute to barrier function improvement on imiquimod-induced psoriasis-like dermatitis animal model via the downregulation of interleukin-23. Experimental and therapeutic medicine, 21(5), 448. https://doi.org/10.3892/etm.2021.9876
Guo, Jiun-Wen, et al. "Magnolol may contribute to barrier function improvement on imiquimod-induced psoriasis-like dermatitis animal model via the downregulation of interleukin-23." Experimental and therapeutic medicine vol. 21,5 (2021): 448. doi: https://doi.org/10.3892/etm.2021.9876
Guo JW, Cheng YP, Liu CY, Thong HY, Lo Y, Wu CY, Jee SH. Magnolol may contribute to barrier function improvement on imiquimod-induced psoriasis-like dermatitis animal model via the downregulation of interleukin-23. Exp Ther Med. 2021 May;21(5):448. doi: 10.3892/etm.2021.9876. Epub 2021 Mar 01. PMID: 33747183; PMCID: PMC7967813.
Copy Download .nbib Format: NLM
Histiocytoid Sweet syndrome successfully treated with etanercept.

Proceedings (Baylor University. Medical Center)

Watson IT, Haugh I, Gardner AR, Menter MA.
PMID: 29904308
Proc (Bayl Univ Med Cent). 2018 May 09;31(3):347-349. doi: 10.1080/08998280.2018.1460132. eCollection 2018 Jul.

We report the first case of a 34-year-old woman with histiocytoid Sweet syndrome (HSS) that was successfully treated with etanercept. HSS is a rare histological variant of acute febrile neutrophilic dermatosis that was described by Requena et al in...

Cite
Watson IT, Haugh I, Gardner AR, et al. Histiocytoid Sweet syndrome successfully treated with etanercept. Proc (Bayl Univ Med Cent). 2018;31(3):347-349doi: 10.1080/08998280.2018.1460132.
Watson, I. T., Haugh, I., Gardner, A. R., & Menter, M. A. (2018). Histiocytoid Sweet syndrome successfully treated with etanercept. Proceedings (Baylor University. Medical Center), 31(3), 347-349. https://doi.org/10.1080/08998280.2018.1460132
Watson, Ian T, et al. "Histiocytoid Sweet syndrome successfully treated with etanercept." Proceedings (Baylor University. Medical Center) vol. 31,3 (2018): 347-349. doi: https://doi.org/10.1080/08998280.2018.1460132
Watson IT, Haugh I, Gardner AR, Menter MA. Histiocytoid Sweet syndrome successfully treated with etanercept. Proc (Bayl Univ Med Cent). 2018 May 09;31(3):347-349. doi: 10.1080/08998280.2018.1460132. eCollection 2018 Jul. PMID: 29904308; PMCID: PMC5997035.
Copy Download .nbib Format: NLM
Evaluations of Quality by Design (QbD) Elements Impact for Developing Niosomes as a Promising Topical Drug Delivery Platform.

Pharmaceutics

Shah P, Goodyear B, Haq A, Puri V, Michniak-Kohn B.
PMID: 32182792
Pharmaceutics. 2020 Mar 09;12(3). doi: 10.3390/pharmaceutics12030246.

Topical corticosteroids are used to treat a variety of skin conditions such as allergic reactions, eczema, and psoriasis. Niosomes are a novel surfactant-based delivery system that may be used to deliver desoximetasone via topical product application in order to...

Cite
Shah P, Goodyear B, Haq A, et al. Evaluations of Quality by Design (QbD) Elements Impact for Developing Niosomes as a Promising Topical Drug Delivery Platform. Pharmaceutics. 2020;12(3)doi: 10.3390/pharmaceutics12030246.
Shah, P., Goodyear, B., Haq, A., Puri, V., & Michniak-Kohn, B. (2020). Evaluations of Quality by Design (QbD) Elements Impact for Developing Niosomes as a Promising Topical Drug Delivery Platform. Pharmaceutics, 12(3), . https://doi.org/10.3390/pharmaceutics12030246
Shah, Parinbhai, et al. "Evaluations of Quality by Design (QbD) Elements Impact for Developing Niosomes as a Promising Topical Drug Delivery Platform." Pharmaceutics vol. 12,3 (2020). doi: https://doi.org/10.3390/pharmaceutics12030246
Shah P, Goodyear B, Haq A, Puri V, Michniak-Kohn B. Evaluations of Quality by Design (QbD) Elements Impact for Developing Niosomes as a Promising Topical Drug Delivery Platform. Pharmaceutics. 2020 Mar 09;12(3). doi: 10.3390/pharmaceutics12030246. PMID: 32182792; PMCID: PMC7150869.
Copy Download .nbib Format: NLM
A case of bleomycin-induced flagellate dermatitis: A case report.

SAGE open medical case reports

Cullingham K, Kost G.
PMID: 34484791
SAGE Open Med Case Rep. 2021 Aug 31;9:2050313X211039476. doi: 10.1177/2050313X211039476. eCollection 2021.

The article description and significance to dermatologists: bleomycin flagellate dermatitis is a rare cutaneous manifestation, believed to be due to the lack of bleomycin hydrolase enzyme in the skin, which inactivates bleomycin, resulting in its accumulation. This is thought...

Cite
Cullingham K, Kost G. A case of bleomycin-induced flagellate dermatitis: A case report. SAGE Open Med Case Rep. 2021;9:2050313X211039476doi: 10.1177/2050313X211039476.
Cullingham, K., & Kost, G. (2021). A case of bleomycin-induced flagellate dermatitis: A case report. SAGE open medical case reports, 92050313X211039476. https://doi.org/10.1177/2050313X211039476
Cullingham, Kyle, and Kost, Gregory. "A case of bleomycin-induced flagellate dermatitis: A case report." SAGE open medical case reports vol. 9 (2021): 2050313X211039476. doi: https://doi.org/10.1177/2050313X211039476
Cullingham K, Kost G. A case of bleomycin-induced flagellate dermatitis: A case report. SAGE Open Med Case Rep. 2021 Aug 31;9:2050313X211039476. doi: 10.1177/2050313X211039476. eCollection 2021. PMID: 34484791; PMCID: PMC8411647.
Copy Download .nbib Format: NLM
Salvianolic Acid B in Microemulsion Formulation Provided Sufficient Hydration for Dry Skin and Ameliorated the Severity of Imiquimod-Induced Psoriasis-Like Dermatitis in Mice.

Pharmaceutics

Guo JW, Cheng YP, Liu CY, Thong HY, Huang CJ, Lo Y, Wu CY, Jee SH.
PMID: 32429542
Pharmaceutics. 2020 May 17;12(5). doi: 10.3390/pharmaceutics12050457.

Psoriasis is a chronic inflammatory skin disorder with a pathogenesis involving the interleukin-23/interleukin-17 axis. Salvianolic acid B exerts several pharmacological effects, such as antioxidation, anti-inflammation, and antitumor effects. The anti-psoriatic effects of salvianolic acid B have not been reported....

Cite
Guo JW, Cheng YP, Liu CY, et al. Salvianolic Acid B in Microemulsion Formulation Provided Sufficient Hydration for Dry Skin and Ameliorated the Severity of Imiquimod-Induced Psoriasis-Like Dermatitis in Mice. Pharmaceutics. 2020;12(5)doi: 10.3390/pharmaceutics12050457.
Guo, J. W., Cheng, Y. P., Liu, C. Y., Thong, H. Y., Huang, C. J., Lo, Y., Wu, C. Y., & Jee, S. H. (2020). Salvianolic Acid B in Microemulsion Formulation Provided Sufficient Hydration for Dry Skin and Ameliorated the Severity of Imiquimod-Induced Psoriasis-Like Dermatitis in Mice. Pharmaceutics, 12(5), . https://doi.org/10.3390/pharmaceutics12050457
Guo, Jiun-Wen, et al. "Salvianolic Acid B in Microemulsion Formulation Provided Sufficient Hydration for Dry Skin and Ameliorated the Severity of Imiquimod-Induced Psoriasis-Like Dermatitis in Mice." Pharmaceutics vol. 12,5 (2020). doi: https://doi.org/10.3390/pharmaceutics12050457
Guo JW, Cheng YP, Liu CY, Thong HY, Huang CJ, Lo Y, Wu CY, Jee SH. Salvianolic Acid B in Microemulsion Formulation Provided Sufficient Hydration for Dry Skin and Ameliorated the Severity of Imiquimod-Induced Psoriasis-Like Dermatitis in Mice. Pharmaceutics. 2020 May 17;12(5). doi: 10.3390/pharmaceutics12050457. PMID: 32429542; PMCID: PMC7284938.
Copy Download .nbib Format: NLM
An Open-label, Observational Study Evaluating Desoximetasone Topical Spray 0.25% in Patients with Scalp Psoriasis.

The Journal of clinical and aesthetic dermatology

Bagel J, Nelson E.
PMID: 29785235
J Clin Aesthet Dermatol. 2018 May;11(5):27-29. Epub 2018 May 01.

No abstract available.

Cite
Bagel J, Nelson E. An Open-label, Observational Study Evaluating Desoximetasone Topical Spray 0.25% in Patients with Scalp Psoriasis. J Clin Aesthet Dermatol. 2018;11(5):27-29
Bagel, J., & Nelson, E. (2018). An Open-label, Observational Study Evaluating Desoximetasone Topical Spray 0.25% in Patients with Scalp Psoriasis. The Journal of clinical and aesthetic dermatology, 11(5), 27-29.
Bagel, Jerry, and Nelson, Elise. "An Open-label, Observational Study Evaluating Desoximetasone Topical Spray 0.25% in Patients with Scalp Psoriasis." The Journal of clinical and aesthetic dermatology vol. 11,5 (2018): 27-29.
Bagel J, Nelson E. An Open-label, Observational Study Evaluating Desoximetasone Topical Spray 0.25% in Patients with Scalp Psoriasis. J Clin Aesthet Dermatol. 2018 May;11(5):27-29. Epub 2018 May 01. PMID: 29785235; PMCID: PMC5955630.
Copy Download .nbib Format: NLM
Development of an .

Turkish journal of pharmaceutical sciences

Sainy J, Atneriya U, Kori JL, Maheshwari R.
PMID: 34496553
Turk J Pharm Sci. 2021 Sep 01;18(4):465-475. doi: 10.4274/tjps.galenos.2020.33239.

OBJECTIVES: Desoximetasone (DMS) is a widely recommended drug for the topical treatment of plaque psoriasis. However, low water solubility and short half life of DMS present major obstacles in the development of an effective topical formulation. Thus, there is...

Cite
Sainy J, Atneriya U, Kori JL, et al. Development of an . Turk J Pharm Sci. 2021;18(4):465-475doi: 10.4274/tjps.galenos.2020.33239.
Sainy, J., Atneriya, U., Kori, J. L., & Maheshwari, R. (2021). Development of an . Turkish journal of pharmaceutical sciences, 18(4), 465-475. https://doi.org/10.4274/tjps.galenos.2020.33239
Sainy, Jitendra, et al. "Development of an ." Turkish journal of pharmaceutical sciences vol. 18,4 (2021): 465-475. doi: https://doi.org/10.4274/tjps.galenos.2020.33239
Sainy J, Atneriya U, Kori JL, Maheshwari R. Development of an . Turk J Pharm Sci. 2021 Sep 01;18(4):465-475. doi: 10.4274/tjps.galenos.2020.33239. PMID: 34496553; PMCID: PMC8430412.
Copy Download .nbib Format: NLM
Showing 1 to 7 of 7 entries